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Abstract
Background: Hepatic Flare (HF) after initiation of highly active antiretroviral therapy (HAART) in HIV-HBV coinfected
individuals is well recognized but prospective data on predictors and subsequent outcome are limited.
Methods: The Tenofovir in HIV-HBV coinfection study was a randomized clinical trial of HBV-active HAART
including lamivudine and/or tenofovir in antiretroviral naïve HIV-HBV individuals in Thailand.
Results: Early HF (EHF) was defined as ALT > 5 × ULN during the first 12 weeks. EHF was observed in 8 (22%) of
individuals at a median of 56 days. 6/8 EHF cases were asymptomatic and resolved with HAART continuation,
however one subject with underlying cirrhosis died following rapid hepatic decompensation. EHF was significantly
associated with higher baseline ALT (79 IU/L vs 36 IU/L non-EHF, p = 0.008) and HBV DNA (9.9 log10 c/ml vs 8.4
log10 c/ml non EHF, p = 0.009), and subsequent serological change. HBeAg loss occurred in 75% of EHF cases
versus 22% in non-EHF (p = 0.04), and HBsAg loss in 25% of EHF cases versus 4% of non-EHF (p = 0.053).
Conclusion: EHF after HBV active HAART initiation was frequently observed in this population. Timing of EHF,
association with elevated ALT and HBV DNA and high rate of seroconversion are all consistent with immune
restoration as the likely underlying process.
Clinical Trial number: NCT00192595.
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Background
Hepatotoxicity (HT) after HAART initiation has been
reported in 2-14% of HIV positive individuals [1-3], and
the risk increases significantly in HBV or HCV coin-
fected individuals [1,4]. Definitions of HT vary but the
most commonly used is based on the AIDS Clinical
Trial Group (ACTG) criteria in which an increase in
ALT and/or AST above 5 × upper limit of normal
( U L N )( G r a d e3 )i sd e f i n e da ss e v e r eH T .H F( H F )
appears to be particularly common within the first
months after HAART initiation, suggesting a potential
immunological component to its development. The
outcome following HF may be beneficial with subse-
quent serological change; on the other it may also be
associated with morbidity, and even mortality. Although,
HF after initiation of HAART in HIV-HBV coinfected
individuals is well recognized, prospective data on pre-
dictors and subsequent outcome are limited.
We therefore examined the incidence, characteristics,
predictors and subsequent outcome of HF occurring in
the first 12 weeks after HAART initiation (early HF
[EHF ]) within the Tenofovir in Coinfection study
(TICO), a randomized clinical trial of HBV-active
HAART including lamivudine and/or tenofovir in 36
antiretroviral (ARV) naïve HIV-HBV individuals in
Thailand. * Correspondence: gmatthews@kirby.unsw.edu.au
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Full eligibility criteria for this study are given elsewhere
[5], but in brief, subjects were HIV-1 antibody positive
and naïve to ARV with chronic hepatitis B infection
(HBV surface antigen (HBsAg)-positive > 6 months
apart with HBV DNA > 100,000 copies/mL). Subjects
were excluded if they had evidence of other causes for
chronic liver disease ie hepatitis C virus, acute hepatitis
A virus, autoimmune disease, serum ALT level > 1000
IU/L. Early HF was defined as ALT > 5 × ULN during
the first 12 weeks.
Liver function tests (LFTs) were routinely performed
a tw e e k s0 ,4 ,8 ,1 2 ,2 4 ,3 6a n d4 8 .P l a s m af o rH B V
DNA testing and peripheral blood mononuclear cells
(PBMC) were collected at weeks 0, 4, 8 and 12, 24 and
48 and stored at -80 C and -140 C respectively. HBV
DNA levels were analysed at the Victorian Infectious
Diseases Laboratory (VIDRL), Melbourne, Australia.
HBV DNA measurement was performed by the Versant
HBV DNA 3.0 bDNA assay (Siemens HealthCare, Tar-
rytown, NY, USA). The linear dynamic range of the
assay was from 2 × 10
3 -1×1 0
8 copies/mL.
All subjects gave written informed consent and the
relevant Human Research Ethics Committees in Thai-
land and Australia approved the study.
Statistical analysis
Cases were identified using the pre-defined criteria as
stated above and compared with non-cases in regard to
baseline characteristics using standard descriptive statis-
tics. Differences between HF and non-HF cases were
compared using the Mann-Whitney U-test or Chi-
square test. Univariate analyses were performed to iden-
tify variables associated with development of hepatic
flare. Data were analysed using STATA (StataCorp, Col-
lege Station, Tx, USA).
Results
Thirty-six advanced HIV/HBV co-infected patients with
a median CD4 count of 36 cells/mm
3 (interquartile
range (IQR) 19-208 cells/mm
3)a n dH I VR N Ao f4 . 7
log10 c/ml (IQR 4.3-5.1 log10 c/ml) were enrolled. HBV
DNA was high at baseline (median 8.4 log10 c/ml, IQR
8.1-9.5 log10 c/ml), 61% of the group were HBeAg posi-
tive and 53% had normal baseline ALT. Twenty-nine
patients (81%) were infected with HBV genotype C.
Seven (19%) had experienced a prior AIDS defining ill-
ness, six (17%) were on isoniazid and rifampicin for
tuberculous treatment. Twenty-four (67%) and 58%
were on co-trimoxazole and fluconazole, respectively,
for opportunistic infection (OI) prophylaxis.
EHF was observed in 8 (22%) individuals at a median
of 56 days (range 21-86 days) with a median peak ALT
of 395 IU/L (range 178-2560 IU/L). Six of the 8 EHF
cases were asymptomatic and resolved with continuation
of HAART. In this group, 3/4 HBeAg positive subjects
subsequent lost HBeAg; one also experienced HBsAg
loss and another had HBsAg loss with anti-HBs sero-
conversion, all had ALT < 2 × ULN and undetectable
HBV DNA (< 200 c/ml) at week48.
Two cases of EHF were clinically symptomatic, one of
whom had underlying cirrhosis and died following rapid
hepatic decompensation. The other was a 37 yr old
HBeAg negative man with a baseline CD4 count of
20cells/mm
3,H B VD N Ao f1 0 . 0l o g 10c/ml and baseline
ALT of 78 IU/L. He commenced a regimen of AZT/
3TC/EFV. At week 8 the subject presented with nausea
and jaundice and was found to have an ALT of 2560
IU/L. Efavirenz was switched to lopinavir/ritonavir and
HAART was continued with close observation. LFTs
subsequently improved and by week 48 had normalised
with undetectable HIV and HBV viral load but no loss
of HBsAg. After week48, EFV was subsequently reintro-
duced with no further rise in transaminase values.
Baseline characteristics of EHF cases and non-EHF
cases are given in Table 1.
EHF cases had significantly higher baseline ALT (79
IU/L vs 36 IU/L, p = 0.008) and HBV DNA (9.9 log10 c/
ml vs 8.4 log10 c/ml, p = 0.009) than non-EHF cases.
Table 1 Univariate analysis of predictors of early hepatic
flare.
EHF
(n = 8)
Non-EHF
(n = 28)
p-
value
Age yrs (median, IQR) 37 (33-42) 33 (28-40) 0.25
Male gender 88% 43% 0.12
HBeAg positive 50% 64% 0.47
Alcohol (> 3units/day) 25% 25% 1.00
Cirrhosis 20% 42% 0.36
HBV Genotype C 75% 82% 0.28
BMI kg/m
2 (median. IQR) 19 (18-20) 20 (18-22) 0.20
BL CD4 cells/mm
3 (median. IQR) 52 (18-131) 32 (19-214) 0.96
BL HIV RNA log10 c/ml (median.
IQR)
4.9 (4.7-5.1) 4.7 (4.3-5.1) 0.22
BL ALT IU/L (median. IQR) 79 (59-96) 36 (22-59) 0.008*
BL HBV DNA log10 c/ml (median.
IQR)
9.9 (8.4-10.4) 8.4 (7.8-9.0) 0.009*
Randomised HBV therapy 3TC n = 5 3TC n = 8 0.193
TDF n = 2 TDF n = 10
3TC/TDF n
=1
3TC/TDF n =
10
OI prophylaxis
(fluconazole and/or
cotrimoxazole)
88% 61% 0.162
Izoniazid therapy 0% 21% 0.302
All comparisons made using the Mann-Whitney U-test except categorical
variables where Chi-squared or Fischers Exact test used
*Statistically significant at p < 0.05
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age, gender, HBV genotype, HIV related parameters
(CD4 count and HIV RNA) or use of potentially hepato-
toxic agents (izoniazid/rifampicin/fluconazole/cotrimox-
azole/alcohol) prior to HAART initiation. Similarly no
significant differences were observed by randomised
therapy, although EHF was seen in 38% of subjects in
the arm containing 3TC alone versus 15% of subjects on
TDF-containing regimens (p = 0.078).
ALT and HBV DNA remained significantly higher in
the EHF group throughout the first 12 weeks of therapy
( F i g u r e1 )a l t h o u g hb yw e e k1 2t h ed i f f e r e n c ei nH B V
DNA between groups had become non-significant
(4.31log10c/ml vs 3.88 log10 c/ml, p = 0.96). The reduc-
tion in HBV DNA between weeks 0 and 12 was signifi-
cantly greater in the subjects who experienced HF than
those that did not (p = 0.039). ALT remained signifi-
cantly higher in the EHF group at week 12 of therapy
(median 153 IU/L vs 36 IU/L, p = 0.03) but was similar
to the non-EHF group by wk 24 (median 31 IU/L vs 43
IU/L, p = 0.26) and all time points thereafter.
EHF was associated with subsequent HBV serological
change. HBeAg loss occurred in 75% of EHF cases ver-
sus 22% in non-EHF (p =0 . 0 4 ) ,a n dH B s A gl o s si n
25% of EHF cases versus 4% of non-EHF (p =0 . 0 5 3 ) .
In fact, the case of HBsAg loss in the non-EHF group
was a subject who experienced a late HF with an ALT
rise to 254 IU/L at week 24 having previously been
normal. Follow-up serological testing demonstrated
anti-HBe seroconversion and HBsAg loss in this sub-
ject. This was the only other subject in the study to
experience HF after HAART initiation, giving an over-
all rate of HF of 25% over 48 weeks. Both HBeAg and
HBsAg loss were significantly predicted by the occur-
rence of any HF. Among HBeAg positive subjects, 80%
of cases with HF at any time point experienced HBeAg
loss compared with 18% in those without HF (p =
0.009), and among all subjects 33% of HF cases experi-
enced HBsAg loss compared to 0% in subjects without
any HF (p =0 . 0 0 2 ) .
Discussion
EHF after HBV active HAART initiation was frequently
observed in this population.
We found that elevated ALT and higher HBV DNA at
baseline are significant predictors of EHF. In addition
t h eo c c u r r e n c eo fE H Fw a sp o s i t i v e l ya s s o c i a t e dw i t h
subsequent HBeAg and HBsAg loss, both of which
occurred at elevated rates (33% and 8% respectively)
during the 48-week study follow-up.
Elevated transaminases in the setting of HAART and
viral hepatitis co-infection are commonly multifactorial
and may reflect natural alterations in hepatitis disease
activity, direct antitretroviral hepatotoxicty, drug hyper-
sensitivity, co-existent hepatotoxic medication, alcohol
excess and immune restoration disease. The reasons for
Figure 1 ALT and HBV DNA values in HF and non-HF subjects over 1
st 12 weeks after HAART initiation. -axis: Weeks after HAART
initiation. y-axis 1: HBV DNA log 10 c/ml. y-axis 2: ALT IU/L.
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trial are unclear but can be hypothesized.
Our population had advanced immunodeficiency with
a median pre-HAART CD4 count of only 36 cells/mm
3
and high usage of potentially hepatotoxic medications
including cotrimoxazole, fluconazole and isoniazid/
rifampicin - however none of these factors were identi-
fied as associated with EHF in univariate analysis. Simi-
larly, no difference was observed in baseline level of
alcohol use between groups (Table 1). Nucleoside analo-
gue agents are also potentially hepatotoxic, but usually
through the development of mitochondrial dysfunction
and microvesicular hepatic steatosis - this was felt to be
unlikely in our subjects given the time frame in which
the HF events were observed and the absence of asso-
ciated features such as lactic acidosis suggesting mito-
chondrial dysfunction. All subjects were prescribed EFV
and EFV associated hepatotoxicity has been clearly
described, although at a lesser rate than with nevirapine
[4,6]. EFV induced hepatotoxicity as a cause of HF is
possible in the symptomatic case, (although subsequent
EFV reintroduction without HF at a later date makes
this unlikely); and the possibility of EFV-induced hepa-
totoxicity as a cause of death in the case with cirrhosis
is also conceivable.
Overall however, timing of EHF, association with ele-
vated ALT and HBV DNA and high rate of seroconver-
sion are all consistent with immune restoration
stimulating HBV-specific immune responses as the likely
underlying process
Spontaneous flares in CHB are well recognised and
reflect the dynamic nature of the balance between
immunological control and HBV replication [7]. Some-
times, but not universally, these flares will be followed
by HBeAg loss, anti-HBe seroconversion and even occa-
sionally HBsAg loss/seroconversion. In the context of
HBV treatment and effective HBV DNA reduction the
rate of HF increases, particularly in the early months of
treatment [8,9]. These flares likely reflect an underlying
shift in host-viral balance with some regeneration of
host T-cell responsiveness as HBV DNA decreases [10],
but are still accompanied by anti-HBe seroconversion in
around only 20% of subjects by 1 year [8].
In the setting of HIV coinfection the situation is
enhanced by the simultaneous reduction in HIV RNA
observed with effective HAART and the subsequent
restoration of either an adaptive or innate response to
HBV antigens. The concept of immune restoration dis-
ease (IRD) is characterised by the finding of rapid
restoration in immunity in the presence of a high patho-
gen load resulting in abnormal and exaggerated immune
responses, often mediated by high levels of interferon
gamma [11-13]. Besides elevated ALT, our study identi-
fied higher HBV viral load both at baseline and
throughout the early weeks of therapy, as a significant
predictor of EHF, a finding consistent with the theory of
IRD and high antigen burden as a cause for flare in
these subjects. This theory is supported by our findings
of elevated CXCL10, an interferon stimulated gene, in
patients with EHF within this study [14].
The most striking aspect of our study however is the
link between HF and the high rate of subsequent sero-
conversion. In a retrospective study examining the role
of 3TC-containing HAART on serological change in 82
HIV-HBV coinfected subjects, Miailhes et al reported an
anti-HBe seroconversion rate of 17% and an overall
HBsAg loss rate of 6% during a median follow-up of 5
years [15]. Interesting, they found more advanced HIV
CDC stage at baseline to be associated with subsequent
seroconversion rates. HBsAg and/or HBeAg seroconver-
sion occurred in 29% of stage C subjects versus only 3%
of patients with stage A disease, again suggesting a
major role for immunorestoration in promoting sero-
conversion. One specific difference in our study to the
majority of reports on outcomes in HIV-HBV coinfected
individuals commencing HAART is that our population
was Asian with predominantly Genotype C and likely
vertically acquired HBV disease. Thus differences in the
virus, host and/or natural history of HBV in this popula-
tion may all be contributing to our findings. Given the
overwhelming greater burden of HBV disease in Asian
countries, further study of the mechanisms and out-
comes of HBV-active HAART in this population are
certainly required.
Our study is undoubtedly limited by the relatively
small number of subjects to elucidate further any addi-
tional associations or conclusions. However, it is one of
the few randomised clinical trials performed in this
population.
Conclusion
The rate of HF is high during the first 12 weeks of
HBV-active HAART initiation in an advanced immuno-
deficient Asian population. Although the mechanisms
underlying this may be multifactorial, our findings most
strongly support a significant role for HBV immune
restoration disease as the major contributing factor. A
strategy of short-course lead-in anti-HBV therapy (using
drugs without anti-HIV activity) could be studied as a
potential mechanism to decrease HBV burden and pre-
vent HF after HAART initiation in such individuals.
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